dpp-4 inhibitors and glp-1 agonists Frontiers Dipeptidyl peptidase 4 inhibitors in
Description
Pricing reflects coverage for clinical care & multi-mo

supplementary table R)

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

doi: 10.1038/s41598-020-65873-6

221,222 Activation of Akt stimulates -cell proliferation, reduces apoptosis, and enhances insulin secretion by regulating downstream effector molecules like Forkhead box protein O1 (FoxO1) and the glucose transporter type 2 (GLUT2)

We have examined seven ways these treatments improve health outcomes across multiple body systems
